Recent Updates
Recently added Catalysts
WVE Positive Sentiment

Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

Key Takeaway: Wave Life Sciences Ltd. will host a live webcast on November 12, 2024, to review its third quarter financial results and discuss business updates. The company is a clinical-stage biotechnology firm focused on RNA medicines, with a diversified pipeline that includes programs for Duchenne muscular dystrophy and other conditions. The event aims to provide insights into the company's progress and financial standing.
Price reaction · baseline $13.83 (2024-11-01 close) · clean, no other WVE news in the window
day 0 close · peak
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Wave Life Sciences is actively transforming human health through RNA medicines.
  • The company has a diverse pipeline addressing multiple disorders.
  • Upcoming financial results may indicate positive growth or expansion.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
33.2%
average across 9 past catalysts
Cash runway
~27 mo
Minimal dilution risk
Lead asset
WVE-N531
Phase 2 · Duchenne Muscular Dystrophy

Full Press Release Details

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company’s third quarter 2024 financial results and provide business updates.
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. Once registered, participants will receive the dial-in information.
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X (formerly Twitter) and LinkedIn.

Frequently Asked Questions

When will Wave Life Sciences hold its Q3 2024 conference call?

Wave Life Sciences will host its Q3 2024 conference call on November 12, 2024.

How can I access the Wave Life Sciences webcast?

The webcast can be accessed under 'Investor Events' on the company's website.

What does Wave Life Sciences focus on?

Wave Life Sciences specializes in RNA medicines aimed at improving human health.

What diseases are included in Wave's clinical programs?

Their clinical programs include Duchenne muscular dystrophy and Huntington's disease.

Where is Wave Life Sciences located?

Wave Life Sciences is headquartered in Cambridge, Massachusetts.

Last updated: Nov 4, 2024